Drug targets

A new app note, brought to you by BellBrook Labs and supported by DDW, is available to download for free here.  Clinical trials continue to determine whether therapeutic modulation of kinases can be used to suppress the immune system in autoimmune diseases or stimulate for antiviral and cancer immunotherapy. The discovery and characterisation of small molecule modulators have […]

Integrated DNA Technologies (IDT) has released Alt-R HDR Donor Blocks, a solution for increasing homology-directed repair (HDR) rates in large fragment knock-in experiments.   How does Alt-R HDR work?  The Alt-R HDR Donor Blocks incorporate advanced chemical modifications to boost the HDR rates of large genomic changes and insertions, and significantly reduce the occurrence of non-homologous […]

News round-up by DDW’s Megan Thomas for 31 January – 4 February, 2022  This week, DDW’s Megan Thomas has rounded up five stories that highlight the impact of research, breakthroughs, agreements and trials in the drug discovery world.  1. Researchers discover way to disarm potentially deadly Listeria bacteria  University of Queensland researchers have discovered a […]

A new app note, brought to you by BellBrook Labs and supported by DDW, is available to download for free here.  Clinical trials continue to determine whether therapeutic modulation of kinases can be used to suppress the immune system in autoimmune diseases or stimulate for antiviral and cancer immunotherapy. The discovery and characterisation of small molecule modulators have […]

Brad Loren, Matthew Marrone, and Christopher Singer, of intellectual property and technology law firm McAndrews, Held & Malloy, on quantum computing and its benefits to drug discovery.  Explaining quantum computing and its promise  Before we explore how QC can benefit drug discovery and drug development, let us first take a step back and explore what QC actually […]

PhoreMost, a UK-based biopharmaceutical company developing drugs against intractable disease targets, and Polaris Quantum Biotech (POLARISqb), a NC-based quantum computing drug design company, have collaborated to study oncology targets currently considered undruggable.   The agreement  The POLARISqb Tachyon quantum computing platform will be used to scan billions of molecules from a large chemical space, to find novel molecular […]

The Drug Discovery Unit (DDU) in the School of Life Sciences at The University of Dundee is using Iktos’ generative modelling artificial intelligence (AI) technology in one of its drug discovery programmes.  The collaboration   Iktos will apply its de novo ligand and structure-based generative modelling technologies, its AI-based retrosynthesis analysis and planning tool to complement DDU’s drug discovery […]

CAR T cell technology provides the foundation for established immunotherapies against certain types of blood cancer and holds great promise for the fight against many solid tumours too. One major drawback of conventional CAR T cell technology, which relies on a single target antigen, is the lack of tumour-associated antigens (TAAs) that are truly specific for cancer cells. […]

Neurocrine Biosciences and Sosei Group Corporation have collaborated to develop novel muscarinic receptor agonists, which Neurocrine Biosciences intends to study in the treatment for schizophrenia, dementia and other neuropsychiatric disorders.  The agreement terms  Under the terms of the agreement, Neurocrine Biosciences gains development and commercialisation rights to a broad portfolio of novel clinical and preclinical subtype-selective muscarinic […]

Affibody partnered with ACELYRIN to develop and commercialise izokibep, a bispecific molecule targeting interleukin-17A (IL-17), for multiple autoimmune diseases.   Izokibep is an antibody mimetic, IL-17A inhibitor designed to overcome the limitations of monoclonal antibodies. With extraordinary potency and small molecular size, izokibep can reach high drug exposure levels through a single subcutaneous injection that monoclonal antibodies require IV administration to […]